Published in Cancer on April 01, 2007
Phospholipase D: enzymology, functionality, and chemical modulation. Chem Rev (2011) 1.66
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal (2009) 1.53
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res (2008) 1.43
Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother (2009) 1.33
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.25
Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med (2012) 1.13
Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC Cancer (2008) 0.98
Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol (2014) 0.96
The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther (2008) 0.94
Identifying new small molecule anti-invasive compounds for glioma treatment. Cell Cycle (2013) 0.94
Honokiol activates reactive oxygen species-mediated cytoprotective autophagy in human prostate cancer cells. Prostate (2014) 0.93
Honokiol Eliminates Human Oral Cancer Stem-Like Cells Accompanied with Suppression of Wnt/ β -Catenin Signaling and Apoptosis Induction. Evid Based Complement Alternat Med (2013) 0.90
Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. PLoS One (2014) 0.88
Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1 c pathway. Exp Biol Med (Maywood) (2014) 0.83
Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells. Prostate (2011) 0.82
Honokiol inhibits androgen receptor activity in prostate cancer cells. Prostate (2013) 0.80
The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Med Chem (2014) 0.79
Honokiol dimers and magnolol derivatives with new carbon skeletons from the roots of Magnolia officinalis and their inhibitory effects on superoxide anion generation and elastase release. PLoS One (2013) 0.79
Plant-derived anticancer agents: a promising treatment for bone metastasis. Bonekey Rep (2014) 0.75
Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells. Int J Oncol (2016) 0.75
c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells. Cell Cycle (2016) 0.75
Antineoplastic Effects of Honokiol on Melanoma. Biomed Res Int (2017) 0.75
Honokiol suppresses metastasis of renal cell carcinoma by targeting KISS1/KISS1R signaling. Int J Oncol (2015) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 17.47
Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med (2011) 3.09
Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl (2011) 2.79
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2008) 2.67
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc (2007) 2.45
Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem (2003) 2.44
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol (2005) 2.43
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Primary retroperitoneal teratomas: a review of the literature. J Surg Oncol (2004) 2.42
Decreased cancer survival in individuals separated at time of diagnosis: critical period for cancer pathophysiology? Cancer (2009) 2.24
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest (2007) 2.22
Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res (2002) 2.18
Targeted therapy of oral hairy leukoplakia with gentian violet. J Am Acad Dermatol (2008) 2.17
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest (2005) 2.10
Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol (2005) 2.08
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res (2008) 2.01
FDG-PET in radiotherapy treatment planning: Pandora's box? Int J Radiat Oncol Biol Phys (2004) 1.91
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res (2006) 1.85
Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol (2007) 1.81
Variation in course of cavernous nerve with special reference to details of topographic relationships near prostatic apex: histologic study using male cadavers. Urology (2005) 1.80
Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2011) 1.80
Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate (2006) 1.80
A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal (2011) 1.79
Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol (2006) 1.72
PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther (2007) 1.71
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res (2009) 1.70
Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest (2009) 1.68
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem (2008) 1.66
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin (2009) 1.64
Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res (2008) 1.64
Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis (2008) 1.64
A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys (2010) 1.63
Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int (2012) 1.61
Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol (2008) 1.59
Radiation modulation of microRNA in prostate cancer cell lines. Prostate (2008) 1.58
Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line. J Leukoc Biol (2009) 1.57
Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol (2010) 1.57
beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res (2006) 1.55
Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol (2010) 1.55
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol (2007) 1.54
Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow Metab (2007) 1.54
Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. Eur Urol (2009) 1.54
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal (2009) 1.53
Effect of varicocelectomy on patients with unobstructive azoospermia and severe oligospermia. BJU Int (2007) 1.52
Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol (2004) 1.52
Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer (2010) 1.51
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol (2010) 1.49
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol (2007) 1.49
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A (2007) 1.49
Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol (2012) 1.45
Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old. Int Urol Nephrol (2012) 1.44
Radiation exposure of normal temporal bone structures during stereotactically guided gamma knife surgery for vestibular schwannomas. J Neurosurg (2003) 1.44
Long-term changes in renal function outcomes following radical cystectomy and urinary diversion. Int J Clin Oncol (2014) 1.44
Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res (2010) 1.44
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res (2008) 1.43
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol (2008) 1.43
Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.42
Extracapsular tumor extension in cervical lymph nodes: reconciling the literature and seer data. Head Neck (2010) 1.42
Proton beam therapy and accountable care: the challenges ahead. Int J Radiat Oncol Biol Phys (2012) 1.42
Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther (2007) 1.41
Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res (2005) 1.41
Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol (2008) 1.41
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol (2008) 1.41
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem (2010) 1.40
Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models. J Neurosci Methods (2011) 1.40
Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol (2009) 1.39
Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature. Int J Urol (2011) 1.39
Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem (2003) 1.39
RhoA and cytoskeletal disruption mediate reduced osteoblastogenesis and enhanced adipogenesis of human mesenchymal stem cells in modeled microgravity. J Bone Miner Res (2005) 1.38
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A (2010) 1.38
Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate (2007) 1.37
Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res (2011) 1.37
Conventional versus microdissection testicular sperm extraction for nonobstructive azoospermia. J Urol (2002) 1.36
Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation (2002) 1.36
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther (2008) 1.36
Caveolin-1 regulates human immunodeficiency virus-1 Tat-induced alterations of tight junction protein expression via modulation of the Ras signaling. J Neurosci (2008) 1.36